FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019529259> ?p ?o ?g. }

• W2019529259 endingPage "16355" @default.
• W2019529259 startingPage "16347" @default.
• W2019529259 abstract "Vascular endothelial growth factor-mediated angiogenic signal transduction relay is achieved by coordinated induction of endothelial cell proliferation, migration, and differentiation. These complex cellular processes are most likely controlled by activation of both cooperative and antagonistic signals by vascular endothelial growth factor receptors (VEGFRs). Here, we investigated the contribution of tyrosine-phosphorylated residues of VEGFR-2/fetal liver kinase-1 to endothelial cell proliferation and differentiation and activation of signaling proteins. Mutation of tyrosine 1006 of VEGFR-2 to phenylalanine severely impaired the ability of this receptor to stimulate endothelial cell differentiation and tubulogenesis. Paradoxically, the mutant receptor stimulated endothelial cell proliferation far better than the wild-type receptor. Further analysis showed that tyrosine 1006 is responsible for phospholipase Cγ1 (PLCγ1) activation and intracellular calcium release in endothelial cells. Activation of PLCγ1 was selectively mediated by tyrosine 1006. Mutation of tyrosines 799, 820, 949, 994, 1080, 1173, and 1221 had no measurable effect on the ability of VEGFR-2 to stimulate PLCγ1 activation. Association of VEGFR-2 with PLCγ1 was mainly established between tyrosine 1006 and the C-terminal SH2 domain of PLCγ1 in vitro and in vivo. Taken together, the results indicate that phosphorylation of tyrosine 1006 is essential for VEGFR-2-mediated PLCγ1 activation, calcium flux, and cell differentiation. More importantly, VEGFR-2-mediated endothelial cell proliferation is inversely correlated with the ability of VEGFR-2 to associate with and activate PLCγ1. Vascular endothelial growth factor-mediated angiogenic signal transduction relay is achieved by coordinated induction of endothelial cell proliferation, migration, and differentiation. These complex cellular processes are most likely controlled by activation of both cooperative and antagonistic signals by vascular endothelial growth factor receptors (VEGFRs). Here, we investigated the contribution of tyrosine-phosphorylated residues of VEGFR-2/fetal liver kinase-1 to endothelial cell proliferation and differentiation and activation of signaling proteins. Mutation of tyrosine 1006 of VEGFR-2 to phenylalanine severely impaired the ability of this receptor to stimulate endothelial cell differentiation and tubulogenesis. Paradoxically, the mutant receptor stimulated endothelial cell proliferation far better than the wild-type receptor. Further analysis showed that tyrosine 1006 is responsible for phospholipase Cγ1 (PLCγ1) activation and intracellular calcium release in endothelial cells. Activation of PLCγ1 was selectively mediated by tyrosine 1006. Mutation of tyrosines 799, 820, 949, 994, 1080, 1173, and 1221 had no measurable effect on the ability of VEGFR-2 to stimulate PLCγ1 activation. Association of VEGFR-2 with PLCγ1 was mainly established between tyrosine 1006 and the C-terminal SH2 domain of PLCγ1 in vitro and in vivo. Taken together, the results indicate that phosphorylation of tyrosine 1006 is essential for VEGFR-2-mediated PLCγ1 activation, calcium flux, and cell differentiation. More importantly, VEGFR-2-mediated endothelial cell proliferation is inversely correlated with the ability of VEGFR-2 to associate with and activate PLCγ1. Recruitment and activation of phospholipase Cγ1 by vascularendothelial growth factor receptor-2 are required for tubulogenesis anddifferentiation of endothelial cells. Vol. 278 (2003)16347–16355Journal of Biological ChemistryVol. 280Issue 27PreviewUpon reinitiating studies focused on the role of phospholipase Cγ1activation by VEGFR-2 (FLK-1), we obtained results that differed from thosepublished. Extensive analysis of plasmids and use of phospho-specificanti-VEGFR-2 (phospho-tyrosine 1173 VEGFR-2) revealed that the F1173/CKRconstruct, which was used to express F1173/CKR in PAE cells, was not correct;previously the wrong plasmid had been used for those studies. We have repeatedall the analyses reported in the original paper with the correct plasmid. Full-Text PDF Open Access vascular endothelial growth factor VEGF receptor receptor tyrosine kinases phospholipase Cγ1 phosphatidylinositol 3-kinase colony-stimulating factor-1 CSF-1 receptor/fetal liver kinase-1receptor Src homology 2 N-terminal SH2 C-terminal SH2 mitogen-activated protein kinase porcine aortic endothelial Dulbecco's modified Eagle's medium glutathione S-transferase inositol 1,4,5-triphosphate Vascular endothelial growth factor (VEGF)1 exerts its cellular responses by binding to one of its receptors, VEGFR-2/fetal liver kinase-1, and stimulating its autophosphorylation. VEGFR-2 belongs to a subfamily of receptor tyrosine kinases (RTKs) whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, and pathological angiogenesis (1Risau W. Nature. 1997; 386: 671-674Crossref PubMed Scopus (4846) Google Scholar,2Folkman J D'Amore P.A. Cell. 1996; 87: 1153-1155Abstract Full Text Full Text PDF PubMed Scopus (1101) Google Scholar). Although many cellular events involved in angiogenesis, including endothelial cell proliferation, migration, and differentiation, have been extensively characterized, the signal transduction pathways downstream of VEGFR-2, which might mediate these events, are largely limited. Elucidating the precise molecular mechanisms of signal transduction relays involved in angiogenesis is required for design of better anti-angiogenic strategies. Recent studies on VEGFR-2 signal transduction relay have shown that many well characterized signaling proteins such as phospholipase Cγ1 (PLCγ1) and phosphatidylinositol 3-kinase (PI3K) are activated following stimulation of endothelial cells with VEGF (3Takahashi T. Yamaguchi S. Chida K. Shibuya M. EMBO J. 2001; 20: 2768-2778Crossref PubMed Scopus (608) Google Scholar, 4Dayanir V. Meyer R.D. Lashkari K. Rahimi N. J. Biol. Chem. 2001; 276: 17686-17692Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar). However, the role of individual tyrosine residues of VEGFR-2 that might contribute to association and activation of PLCγ1 is not clear and is subject to a great deal of inconsistency within the literature. For example, Cunningham et al. (5Cunningham S.A. Arrate M.P. Brock T.A. Waxham M.N. Biochem. Biophys. Res. Commun. 1997; 240: 635-639Crossref PubMed Scopus (75) Google Scholar) suggested that tyrosines 801 and 1175 of human VEGFR-2 (corresponding to tyrosines 799 and 1173 of mouse VEGFR-2, respectively) are binding sites for PLCγ1. A study by Takahashi et al. (3Takahashi T. Yamaguchi S. Chida K. Shibuya M. EMBO J. 2001; 20: 2768-2778Crossref PubMed Scopus (608) Google Scholar) showed that tyrosine 1175 is a PLCγ1-binding site in VEGFR-2 and that phosphorylation of tyrosine 1175 is required for association and activation of PLCγ1 by VEGFR-2. In contrast, Wu et al. (6Wu L.-W. Mayo L.D. Dunbar J.D. Kessler K.M. Baerwald M.R. Jaffe E.A. Wang D. Warren R.S. Donner D.B. J. Biol. Chem. 2000; 275: 5096-5103Abstract Full Text Full Text PDF PubMed Scopus (256) Google Scholar) suggested that tyrosine 952 (but not tyrosines 801 and 1175) is the PLCγ1-binding site in VEGFR-2. How can these discrepancies within the literature be explained? One possibility is that VEGF-mediated VEGFR-2 autophosphorylation and the ability of VEGFR-2 to recruit signaling proteins are influenced by other endothelial cell-surface receptors such as VEGFR-1, neuropilin-1, and neuropilin-2, which are normally expressed by endothelial cells. Because VEGF binds to all of these receptors, it is highly possible that activation of these receptors and their signal transduction relays are influenced by the presence of these receptors likely due to establishment of receptor homo- and heterodimerization in endothelial cells (7Soker S. Takashima S. Miao H.Q. Neufeld G. Klagsbrun M. Cell. 1998; 92: 735-745Abstract Full Text Full Text PDF PubMed Scopus (2076) Google Scholar, 8Soker S. Miao H.Q. Nomi M. Takashima S. Klagsbrun M. J. Cell. Biochem. 2002; 85: 357-368Crossref PubMed Scopus (380) Google Scholar, 9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar, 10Conway E.M. Collen D. Carmeliet P. Cardiovasc. Res. 2002; 49: 507-521Crossref Scopus (795) Google Scholar). A second possibility is that activation of VEGFR-2 and stimulation of its associated signaling proteins are affected by endothelial cadherins and integrins, adding an additional level of complexity to VEGFR-2-induced signal transduction relays in endothelial cells (11Rahimi N. Kazlauskas A. Mol. Biol. Cell. 1999; 10: 3401-3407Crossref PubMed Scopus (56) Google Scholar, 12Soldi R. Mitola S. Strasly M. Defilippi P. Tarone G. Bussolino F. EMBO J. 1999; 18: 882-892Crossref PubMed Scopus (532) Google Scholar). Finally, it is also possible that individual autophosphorylation sites in VEGFR-2 are not stringently required for the recruitment and association of PLCγ1. If this is true, VEGFR-2 autophosphorylation sites may be compensatory in their ability to associate with PLCγ1. In this study, we have addressed the enigma concerning the recruitment and activation of PLCγ1 by VEGFR-2 by using a unique system of a VEGFR-2 chimera and constructing a panel of VEGFR-2 tyrosine mutants, including tyrosines 799, 820, 949, 994, 1006, 1080, and 1173. In this system, VEGFR-2 is selectively activated by CSF-1 without any contributions from other VEGFRs such as VEGFR-1 and neuropilins. Here, we report the following results. 1) Tyrosine 1006 (but not tyrosines 799, 949, 994, 820, 1080, 1173, and 1221) of VEGFR-2 is responsible for association with and activation of PLCγ1. 2) Association of PLCγ1 with VEGFR-2 is established primarily by the C-terminal SH2 domain of PLCγ1. 3) PLCγ1 activation is required for endothelial cell tubulogenesis and differentiation, but not for VEGFR-2-induced endothelial cell proliferation. Human recombinant CSF-1 was purchased from R&D Systems. Mouse anti-phosphotyrosine (PY-20) and anti-PLCγ antibodies and anti-mouse and anti-rabbit secondary antibodies were purchased from Transduction Laboratories (Lexington, KY). Rabbit anti-MAPK and anti-phospho-MAPK antibodies were purchased from New England Biolabs Inc. (Beverly, MA). Rabbit anti-phospho-PLCγ antibody was purchased from BIOSOURCE (Camarillo, CA). Rabbit anti-VEGFR-2 antibody was made against amino acids corresponding to the kinase insert or carboxyl terminus of VEGFR-2 (9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar).U73122 was purchased from Calbiochem. Mouse anti-phosphotyrosine antibody 4G10 was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Porcine aortic endothelial (PAE) cells expressing CKR and tyrosine mutant receptors were established by a retroviral system as described previously (4Dayanir V. Meyer R.D. Lashkari K. Rahimi N. J. Biol. Chem. 2001; 276: 17686-17692Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). Briefly, cDNAs encoding CKR and tyrosine mutant receptors were cloned into retroviral vector pLNCX2 and transfected into 293-GPG cells. Viral supernatants were collected for 7 days, concentrated by centrifugation, and used as previously described (9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). The VEGFR-2 chimera CKR was used as a template to construct the mutations. CKR was subcloned into the pGEMT cloning vector, and site-directed mutagenesis was carried out using a PCR-based site-directed mutagenesis method (4Dayanir V. Meyer R.D. Lashkari K. Rahimi N. J. Biol. Chem. 2001; 276: 17686-17692Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar, 30Meyer R.D. Dayanir V. Majnoun F. Rahimi N. J. Biol. Chem. 2002; 277: 27081-27087Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar). The resultant mutations were verified by sequencing and were subsequently cloned into the pLNCX2 vector at NotI andSalI sites. PAE cells expressing CKR and tyrosine mutant CKRs were grown under semiconfluent culture conditions in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and supplemented with glutamate, penicillin, and streptomycin and serum-starved overnight in DMEM. Cells were either left resting or stimulated with 40 ng/ml CSF-1 for 10 min at 37 °C. Cells were washed twice with buffer containing 25 mm HEPES (pH 7.4), 150 mm NaCl, and 2 mm Na3VO4 and lysed in lysis buffer (10 mm Tris-HCl, 10% glycerol (pH 7.4), 5 mmEDTA, 50 mm NaCl, 50 mm NaF, 1% Triton X-100, 1 mm phenylmethylsulfonyl fluoride, 2 mmNa3VO4, and 20 μg/ml aprotinin). Proteins were immunoprecipitated using appropriate antibodies. Immunocomplexes were bound to protein A-Sepharose and washed three times with 1.0 ml of lysis buffer. Immunoprecipitates were resolved on an SDS-polyacrylamide gel, and the proteins were transferred to Immobilon membranes. For Western blot analysis, the membranes were incubated for 60 min in blocking solution containing 10 mm Tris-HCl (pH 7.5), 150 mm NaCl, 10 mg/ml bovine serum albumin, and 0.05% Tween 20. The membranes were then incubated with primary antibodies diluted in blocking solution for another 60 min, washed three times with Western rinse, incubated with horseradish peroxidase-conjugated secondary antibodies, washed, and developed with ECL (Amersham Biosciences). Finally, the membranes were stripped by incubation in stripping buffer containing 6.25 mm Tris-HCl (pH 6.8), 2% SDS, and 100 mm β-mercaptoethanol at 50 °C for 30 min; washed with Western rinse; and reprobed with the antibody of interest. The proliferation assay was performed as described (4Dayanir V. Meyer R.D. Lashkari K. Rahimi N. J. Biol. Chem. 2001; 276: 17686-17692Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). Briefly, cells were plated at 2 × 104/ml in 24-well plates containing DMEM supplemented with 10% fetal bovine serum and incubated at 37 °C for 12 h. Cells were then washed once with phosphate-buffered saline and serum-starved overnight in DMEM, and various concentrations of CSF-1 were added. During the last 4 h of incubation, cells were pulsed with [3H]thymidine (0.2 μCi/ml) and harvested. Results for each group were collected from four samples. Each experiment was repeated three times, and essentially the same results were obtained. The data are presented as -fold increase over the control. PAE cells expressing either CKR or tyrosine mutant CKRs were grown on 25-mm round glass coverslips and serum-starved for 12–18 h. Cells were incubated in HEPES-buffered saline solution (137 mm NaCl, 5 mm KCl, 4 mm MgCl2, 3 mmCaCl2·2H2O, 25 mm glucose, and 10 mm HEPES) with 4 μm Fluo-3/AM supplemented with 0.02% pluronic acid in Me2SO for 30 min at 37 °C. After rinsing two times in HEPES-buffered saline solution, the live cells were placed in an open chamber (Molecular Probes, Inc., Eugene, OR) with 500 μl of HEPES solution and positioned on the stage of a Zeiss LSM 510 Axiovert confocal laser scanning microscope equipped with an argon laser. For each experiment, cells were scanned for at least 5–10 s before the addition of CSF-1 to establish a base-line fluorescence reading. All readings were made while continuously scanning the cells every 789 ms (33Klepeis V.E. Cornell-Bell A. Trinkaus-Randall V. J. Cell Sci. 2001; 114: 4185-4195Crossref PubMed Google Scholar). The production of inositol phosphates was measured using 60-mm dishes of PAE cells expressing CKR and tyrosine mutant CKRs labeled for 48 h in DMEM supplemented with 0.1% bovine serum albumin and 1 μCi/ml myo-[H]inositol. The cultures were washed and incubated for 15 min with DMEM containing 0.1% bovine serum albumin, 15 mm HEPES (pH 7.5), and 20 mm LiCl. The medium was then aspirated, and fresh medium with or without 40 ng/ml CSF-1 was added and incubated at 37 °C for 20 min. The culture plates were placed on ice, and the medium was removed before the addition of 1.5 ml of ice-cold methanol/HCl (100:1). The quenched samples were collected, and the plates were rinsed with an additional 1.5 ml of methanol/HCl (100:1). To each sample were added 1.5 ml of HO and 3 ml of CHCl3, and the tubes were mixed by vortexing and left on ice for 30 min. The water-soluble phase was collected, diluted with 2 volumes of water and 1 ml of AG 1-X8 formate resin (Bio-Rad), and incubated for 2 h. The samples were extensively washed with water and then with a solution containing 5 mmdisodium tetraborate and 60 mm sodium formate. Finally, the total inositol phosphates were eluted from the resin with a solution of 0.1 m formic acid and 1.0 m ammonium formate and subjected to scintillation counting. The CHCl3-phase samples containing the phospholipids were dried, redissolved in methanol, and subjected to scintillation counting. Endothelial cell spheroids were generated as previously described (31Korff T. Augustin H.G. J. Cell Biol. 1998; 143: 1341-1352Crossref PubMed Scopus (474) Google Scholar). A defined number of cells were suspended in DMEM containing 1% fetal bovine serum and 0.24% (w/v) carboxymethylcellulose (4000 centipoise) in non-adherent round-bottom 96-well plates under standard cell culture conditions. After 24 h, all cells formed one single spheroid per well (750 cells/spheroid). Spheroids were cultured for 2 days before using them in the in vitro angiogenesis assay in the following manner. Spheroids containing 750 cells were embedded in collagen gels. Eight volumes of collagen were mixed with 1 volume of 10× HEPES-buffered saline solution containing 10% 10× DMEM with phenol red. The pH was adjusted to 7.4 with 0.1 n NaOH. Spheroids were centrifuged and suspended in 9 ml of DMEM containing 0.96% carboxymethylcellulose. Collagen and spheroids were mixed and transferred to prewarmed 24-well plates, and the gels were allowed to polymerize in the incubator. After 30 min, 100 μl of DMEM containing various concentrations of CSF-1 were added on top of the gel. Sprouting and tubulogenesis were observed after 2 days under an inverted phase-contrast microscope (Nikon), and pictures were taken using the SPOT camera system. VEGF binds to multiple endothelial cell-surface receptors, including VEGFR-1, VEGFR-2, neuropilin-1, and neuropilin-2 (7Soker S. Takashima S. Miao H.Q. Neufeld G. Klagsbrun M. Cell. 1998; 92: 735-745Abstract Full Text Full Text PDF PubMed Scopus (2076) Google Scholar, 8Soker S. Miao H.Q. Nomi M. Takashima S. Klagsbrun M. J. Cell. Biochem. 2002; 85: 357-368Crossref PubMed Scopus (380) Google Scholar, 9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar, 10Conway E.M. Collen D. Carmeliet P. Cardiovasc. Res. 2002; 49: 507-521Crossref Scopus (795) Google Scholar, 13Whitaker G.B. Limberg B.J. Rosenbaum J.S. J. Biol. Chem. 2001; 276: 25520-25531Abstract Full Text Full Text PDF PubMed Scopus (247) Google Scholar), by generating potentially homologous and heterologous signaling networks. Because these receptors are very often expressed in endothelial cells, it is difficult to address the activation of specific signaling molecules by the individual receptors. We have recently constructed a VEGFR-2 chimera containing the extracellular domain of human CSF-1 receptor/c-fms fused with the transmembrane and cytoplasmic domains of murine VEGFR-2 (9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). This model allowed us to dissect the function of VEGFR-2 in endothelial cells by selectively stimulating the receptor with CSF-1 (4Dayanir V. Meyer R.D. Lashkari K. Rahimi N. J. Biol. Chem. 2001; 276: 17686-17692Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 29Bourette R.P. Myles G.M. Choi J.L. Rohrschneider L.R. EMBO J. 1997; 16: 5880-5893Crossref PubMed Scopus (91) Google Scholar). Throughout this work, the VEGFR-2 chimera is called CKR. In this study, we used PAE cells expressing CKR and aimed to address the role of individual tyrosine residues in the recruitment and activation of PLCγ1. Initially, we evaluated the kinetics of tyrosine phosphorylation of PLCγ1 by CKR following CSF-1 stimulation. For this purpose, cells were stimulated with CSF-1, and the kinetics of phosphorylation of PLCγ1 was evaluated by subjecting total cell lysates to Western blot analysis using anti-phospho-PLCγ1 antibody that specifically recognizes the active form of PLCγ1. CKR-mediated phosphorylation of PLCγ1 peaked after 10 min of stimulation, was significantly reduced after 30 min, and was not detectable after 45 min of stimulation (Fig.1 A). To test the role of individual tyrosine sites in VEGFR-2-mediated activation of PLCγ1 in PAE cells, we individually replaced tyrosines 799, 820, 949, 994, 1006, 1173, and 1212 with phenylalanine. Fig. 1 C shows the schematic location of these tyrosine sites in VEGFR-2. We initially tested the ability of F799/CKR and F1173/CKR to stimulate PLCγ1 activation. These tyrosine sites are conserved in both human and mouse VEGFR-2, and the corresponding tyrosines in human VEGFR-2 are at positions 801 and 1175, respectively. These tyrosine sites have previously been suggested to bind PLCγ1 (3Takahashi T. Yamaguchi S. Chida K. Shibuya M. EMBO J. 2001; 20: 2768-2778Crossref PubMed Scopus (608) Google Scholar). As demonstrated in Fig.1 D, individual mutation of tyrosines 799 and 1173 in mouse VEGFR-2 had no significant effect on their ability to activate PLCγ1. The data suggest that tyrosines 799 and 1173 are not responsible for PLCγ1 activation and furthermore argue that other tyrosine sites in VEGFR-2 might mediate its activation. To test the contribution of other tyrosine sites in VEGFR-2 to the activation of PLCγ1, additional sites were mutated and expressed in PAE cells. To this end, PAE cells expressing tyrosine mutant CKRs, including tyrosines 820, 949, 994, 1006, and 1221, were stimulated with CSF-1 and analyzed for activation of PLCγ1. As demonstrated in Fig. 1 F, all of the tyrosine mutant receptors, viz. F820/CKR, F949/CKR, F994/CKR, and F1221/CKR, were able to stimulate PLCγ1 activation. In contrast, F1006/CKR failed to stimulate robust activation of PLCγ1 compared with the wild-type receptor and other tyrosine mutant CKRs (Fig.1 F). The data also suggest that, in addition to tyrosines 799 and 1173, the presence of tyrosines 820, 949, 994, and 1221 is not required for PLCγ1 activation by VEGFR-2. Tyrosines 1006 and 1080 are located in the kinase domain of VEGFR-2, adjacent to the N and C termini of the activation loop, respectively (Fig. 2 A). To test the putative contribution of tyrosines 1006 and 1080 to PLCγ1 activation, we generated a double tyrosine mutant receptor in which both tyrosines 1006 and 1080 were replaced with phenylalanine. The resultant receptor was similarly expressed in PAE cells and tested for its ability to activate PLCγ1. As Fig. 2 B shows, ligand-stimulated cells expressing the double mutant receptor (F1006/F1080/CKR) maintained their ability to induce residual activation of PLCγ1. The ability of the double mutant receptor to activate PLCγ1 was not completely diminished and indeed was similar to that of F1006/CKR (Fig. 2 B), suggesting that tyrosine 1080 is not involved in the activation of PLCγ1 by VEGFR-2. In addition, the single tyrosine 1080 mutant was also fully capable of activating PLCγ1, similar to the wild-type receptor (data not shown). To test the role of tyrosines 1006 and 1080 in the ligand-dependent autophosphorylation VEGFR-2, we also analyzed their ligand-dependent tyrosine phosphorylation. As Fig. 2 D demonstrates, mutation of tyrosines 1006 and 1080 had no significant effect on the tyrosine phosphorylation of the receptor, suggesting that these tyrosine residues are not involved in the regulation of ligand-dependent receptor autophosphorylation. To test whether tyrosine 1006 plays a role in VEGFR-2-depdendent activation of MAPK and also to test whether activation of PLCγ1 modulates MAPK activation in this system, we analyzed the ability of this receptor to stimulate MAPK activation. As Fig. 2 F shows, both single mutant (F1006/CKR) and double mutant (F1006/F1080/CKR) receptors were fully able to activate MAPK. The data strongly suggest that activation PLCγ1 is not required for VEGFR-2-mediated phosphorylation of MAPK. Association of PLCγ1 with RTKs is established by its N- and C-SH2 domains (14Rhee S.G. Annu. Rev. Biochem. 2001; 70: 281-312Crossref PubMed Scopus (1220) Google Scholar). However, the N- and C-SH2 domain requirement of PLCγ1 for its activation appears to be distinctive among RTKs whose stimulation leads to PLCγ1 activation (14Rhee S.G. Annu. Rev. Biochem. 2001; 70: 281-312Crossref PubMed Scopus (1220) Google Scholar, 15Chattopadhyay A. Vecchi M. Ji Q. Mernaugh R. Carpenter G. J. Biol. Chem. 1999; 274: 26091-26097Abstract Full Text Full Text PDF PubMed Scopus (115) Google Scholar, 31Korff T. Augustin H.G. J. Cell Biol. 1998; 143: 1341-1352Crossref PubMed Scopus (474) Google Scholar). To test which SH2 domain of PLCγ1 is involved in association with VEGFR-2, we made recombinant GST fusion proteins consisting of the N-SH2, C-SH2, or C- and N-SH2 domains of PLCγ1 and tested their ability to associate with ligand-stimulated CKR in vitro. As shown in Fig.3 B, no significant association between CKR and GST-N-SH2 was observed. Only a modest association of CKR with the C-SH2 domain was detected. In contrast, when both the N- and C-SH2 domains were fused to GST, a strong association between CKR and the GST fusion proteins containing the N- and C-SH2 domains was detected. These results suggest that the presence of the N-SH2 domain of PLCγ1 alone is not sufficient to mediate the association of PLCγ1 with VEGFR-2. In contrast, the C-SH2 domain is, in part, able to associate with VEGFR-2 without the N-SH2 domain. However, the presence of the N-SH2 domain greatly facilitated the ability of the C-SH2 domain to interact with VEGFR-2 (Fig. 3 B), suggesting that the C- and N-SH2 domains of PLCγ1 cooperatively associate with VEGFR-2. To test the contribution of tyrosines 1006 and 1173 to complex formation between CKR and the SH2 domains of PLCγ1, PAE cells expressing either F1006/CKR or F1173/CKR were stimulated with CSF-1, and cell lysates were incubated with GST-C-SH2 and GST-C+N-SH2 recombinant proteins. As shown in Fig. 3 C, the ability of CKR to associate with the SH2 domains of PLCγ1 was significantly reduced when tyrosine 1006 was mutated. In contrast, mutation of tyrosine 1173 did not alter the association of CKR and the SH2 domains of PLCγ1. Altogether, the data suggest the following. (i) The N-SH2 domain of PLCγ1 alone is not sufficient to bind VEGFR-2. (ii) The C-SH2 domain of PLCγ1 binds to VEGFR-2 weakly, but its association with VEGFR-2 is greatly enhanced by the presence of the N-SH2 domain. This suggests that the C- and N-SH2 domains of PLCγ1 are engaged in association with VEGFR-2 in a cooperative manner. (iii) The presence of tyrosine 1006 (but not tyrosine 1173) is required for association of PLCγ1 with VEGFR-2. The immediate consequence of PLCγ1 activation by RTKs is accumulation of IP3 and diacylglycerol. IP3 accumulation stimulates the release of calcium from intracellular stores (14Rhee S.G. Annu. Rev. Biochem. 2001; 70: 281-312Crossref PubMed Scopus (1220) Google Scholar, 15Chattopadhyay A. Vecchi M. Ji Q. Mernaugh R. Carpenter G. J. Biol. Chem. 1999; 274: 26091-26097Abstract Full Text Full Text PDF PubMed Scopus (115) Google Scholar). To test the requirement for tyrosines 1173 and 1006 of VEGFR-2 in IP3 production and calcium release, we tested the ability of F1173/CKR and F1006/CKR to stimulate IP3 production and intracellular calcium release in PAE cells. As depicted in Fig.4 A, stimulation of both CKR and F1173/CKR resulted in robust production of IP3. In contrast, F1006/CKR failed to stimulate a significant amount of IP3 production (Fig. 4 A). In addition, we also evaluated the ability of CKR and tyrosine mutant CKRs to stimulate the intracellular calcium release in PAE cells after stimulation with CSF-1. Fig. 4 B shows that stimulation of PAE cells expressing either CKR or F1173/CKR with CSF-1 caused rapid intracellular calcium release as measured using Fluo-3/AM as a probe. Unlike CKR and F1173/CKR, F1006/CKR completely failed to stimulate intracellular calcium release (Fig. 4 B). Collectively, these results suggest that the presence of tyrosine 1006 (but not tyrosine 1173) of VEGFR-2 is required for IP3 production and intracellular calcium release. One of the functions of VEGFR-2 in endothelial cells is the induction of endothelial cell proliferation (9Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). To test the potential role of tyrosine 1006 of VEGFR-2 in endothelial cell proliferation, we subjected cells expressing CKR, F1173/CKR, F949/CKR, and F1006/CKR to a proliferation assay. As shown in Fig. 5, stimulation of PAE cells expressing CKR, F949/CKR, and F1173/CKR with CSF-1 induced proliferation of PAE cells in a CSF-1-dependent manner. As previously reported," @default.
• W2019529259 created "2016-06-24" @default.
• W2019529259 creator A5031505899 @default.
• W2019529259 creator A5050700218 @default.
• W2019529259 creator A5053196268 @default.
• W2019529259 date "2003-05-01" @default.
• W2019529259 modified "2023-10-15" @default.
• W2019529259 title "Recruitment and Activation of Phospholipase Cγ1 by Vascular Endothelial Growth Factor Receptor-2 Are Required for Tubulogenesis and Differentiation of Endothelial Cells" @default.
• W2019529259 cites W1502806109 @default.
• W2019529259 cites W1679229092 @default.
• W2019529259 cites W1958742527 @default.
• W2019529259 cites W1963348751 @default.
• W2019529259 cites W1969642134 @default.
• W2019529259 cites W1978956506 @default.
• W2019529259 cites W1989217499 @default.
• W2019529259 cites W1997169885 @default.
• W2019529259 cites W1997300044 @default.
• W2019529259 cites W2004360930 @default.
• W2019529259 cites W2010403667 @default.
• W2019529259 cites W2012390831 @default.
• W2019529259 cites W2026006256 @default.
• W2019529259 cites W2027603639 @default.
• W2019529259 cites W2040283898 @default.
• W2019529259 cites W2046525214 @default.
• W2019529259 cites W2049246519 @default.
• W2019529259 cites W2063609977 @default.
• W2019529259 cites W2067817921 @default.
• W2019529259 cites W2069043370 @default.
• W2019529259 cites W2070732456 @default.
• W2019529259 cites W2076932525 @default.
• W2019529259 cites W2077687566 @default.
• W2019529259 cites W2078676742 @default.
• W2019529259 cites W2116126519 @default.
• W2019529259 cites W2135743455 @default.
• W2019529259 cites W2145648498 @default.
• W2019529259 cites W2150228169 @default.
• W2019529259 cites W2168146767 @default.
• W2019529259 cites W2168215545 @default.
• W2019529259 cites W2172253185 @default.
• W2019529259 cites W2341210013 @default.
• W2019529259 cites W330009103 @default.
• W2019529259 doi "https://doi.org/10.1074/jbc.m300259200" @default.
• W2019529259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1459536" @default.
• W2019529259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12598525" @default.
• W2019529259 hasPublicationYear "2003" @default.
• W2019529259 type Work @default.
• W2019529259 sameAs 2019529259 @default.
• W2019529259 citedByCount "69" @default.
• W2019529259 countsByYear W20195292592012 @default.
• W2019529259 countsByYear W20195292592013 @default.
• W2019529259 countsByYear W20195292592014 @default.
• W2019529259 countsByYear W20195292592015 @default.
• W2019529259 countsByYear W20195292592016 @default.
• W2019529259 countsByYear W20195292592017 @default.
• W2019529259 countsByYear W20195292592018 @default.
• W2019529259 countsByYear W20195292592019 @default.
• W2019529259 countsByYear W20195292592022 @default.
• W2019529259 countsByYear W20195292592023 @default.
• W2019529259 crossrefType "journal-article" @default.
• W2019529259 hasAuthorship W2019529259A5031505899 @default.
• W2019529259 hasAuthorship W2019529259A5050700218 @default.
• W2019529259 hasAuthorship W2019529259A5053196268 @default.
• W2019529259 hasBestOaLocation W20195292591 @default.
• W2019529259 hasConcept C103041312 @default.
• W2019529259 hasConcept C12927208 @default.
• W2019529259 hasConcept C146285616 @default.
• W2019529259 hasConcept C150710994 @default.
• W2019529259 hasConcept C15215337 @default.
• W2019529259 hasConcept C167734588 @default.
• W2019529259 hasConcept C170493617 @default.
• W2019529259 hasConcept C181199279 @default.
• W2019529259 hasConcept C185592680 @default.
• W2019529259 hasConcept C2777025900 @default.
• W2019529259 hasConcept C2778597717 @default.
• W2019529259 hasConcept C502942594 @default.
• W2019529259 hasConcept C55493867 @default.
• W2019529259 hasConcept C62478195 @default.
• W2019529259 hasConcept C86803240 @default.
• W2019529259 hasConcept C95444343 @default.
• W2019529259 hasConceptScore W2019529259C103041312 @default.
• W2019529259 hasConceptScore W2019529259C12927208 @default.
• W2019529259 hasConceptScore W2019529259C146285616 @default.
• W2019529259 hasConceptScore W2019529259C150710994 @default.
• W2019529259 hasConceptScore W2019529259C15215337 @default.
• W2019529259 hasConceptScore W2019529259C167734588 @default.
• W2019529259 hasConceptScore W2019529259C170493617 @default.
• W2019529259 hasConceptScore W2019529259C181199279 @default.
• W2019529259 hasConceptScore W2019529259C185592680 @default.
• W2019529259 hasConceptScore W2019529259C2777025900 @default.
• W2019529259 hasConceptScore W2019529259C2778597717 @default.
• W2019529259 hasConceptScore W2019529259C502942594 @default.
• W2019529259 hasConceptScore W2019529259C55493867 @default.
• W2019529259 hasConceptScore W2019529259C62478195 @default.
• W2019529259 hasConceptScore W2019529259C86803240 @default.
• W2019529259 hasConceptScore W2019529259C95444343 @default.
• W2019529259 hasIssue "18" @default.
• W2019529259 hasLocation W20195292591 @default.
• W2019529259 hasLocation W20195292592 @default.

• next